NasdaqGS:HUMABiotechs
Humacyte (HUMA) Valuation Check As DoD Funding Highlights Battlefield Vascular Repair Potential
Humacyte (HUMA) is back on investor radar after the Fiscal Year 2026 U.S. Department of Defense Appropriations Act earmarked funding to evaluate and potentially incorporate biologic vascular repair technologies for traumatic military injuries.
See our latest analysis for Humacyte.
The DoD funding news has arrived alongside sharp short term momentum, with a 1 day share price return of 30.02% and a 7 day gain of 19.61% at a last close of $1.22. However, this sits against a 1 year total...